Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Karuna

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

Top News

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

The Independent UK

Lisa Jarvis: Schizophrenia drug may offer much-needed progress

Next year, doctors might finally have something new to offer people who suffer from schizophrenia: a much-needed drug that can better improve their symptoms without the side effects that too often cause them to stop taking their medications.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness

Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for psychosis in Alzheimer's disease.

Benzinga

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ:KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022. At this time, the escalating conflict in Ukraine…

Benzinga

People

Lisa Jarvis

27 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

TRACON Pharmaceuticals

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.